Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2- breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2- early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocyte levels than luminal tumors. Moreover, significant differences in immune infiltrate composition, assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatory antitumor immune infiltrate composition than luminal ones.
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer / Griguolo, G; Dieci, Mv; Paré, L; Miglietta, F; Generali, Dg; Frassoldati, A; Cavanna, L; Bisagni, G; Piacentini, F; Tagliafico, E; Cagossi, K; Ficarra, G; Prat, A; Conte, P; Guarneri, V.. - In: NPJ BREAST CANCER. - ISSN 2374-4677. - 7:14(2021), pp. 1-5. [10.1038/s41523-021-00223-x]
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer.
Dieci MV;Piacentini F;Tagliafico E;Guarneri V.
2021
Abstract
Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2- breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2- early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocyte levels than luminal tumors. Moreover, significant differences in immune infiltrate composition, assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatory antitumor immune infiltrate composition than luminal ones.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Griguolo 2021.pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
1.23 MB
Formato
Adobe PDF
|
1.23 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
